Cite
HARVARD Citation
Urbina, T. et al. (2022). Delayed inflammation decrease is associated with mortality in Tocilizumab-treated critically ill SARS-CoV-2 patients: A retrospective matched-cohort analysis. Innate immunity. 28 (1), pp. 3-10. [Online].